Insmed, Inc.
INSM
$104.92
+1.02%
Insmed, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, operating within the Biotechnology sector. The company is a specialized player in respiratory and rare diseases, with its commercial portfolio anchored by two approved products, Arikayce and Brinsupri, and a clinical pipeline targeting immunology, inflammation, and neuro-rare conditions. The current investor narrative is dominated by the company's significant revenue growth trajectory and its ongoing transition from a clinical-stage entity to a commercial organization, though this is juxtaposed against persistent and substantial operating losses that fuel debate about its path to profitability and cash burn sustainability.…
INSM
Insmed, Inc.
$104.92
Related headlines
Investment Opinion: Should I buy INSM Today?
Rating: Hold. The core thesis is that while Insmed's revenue growth is compelling, the extreme valuation, unsustainable cash burn, and severe technical damage create an asymmetric risk/reward profile that favors waiting for clearer signs of fundamental stabilization or a more attractive entry point.
Supporting evidence includes the staggering 61.31x trailing PS ratio, which demands heroic growth assumptions; the -$997.58M TTM free cash flow indicating a looming financing event; the net loss that widened year-over-year to -$328.49M; and the stock's severe -48.54% six-month decline which, while potentially overdone, reflects legitimate fundamental concerns not present in the broader market (S&P 500 +10.7%).
The two biggest risks are 1) a dilutive equity offering if cash burn continues at the current pace, and 2) a growth deceleration that collapses the premium sales multiple. This Hold rating would upgrade to Buy if the PS multiple compresses further toward 35x (its historical low) on sustained revenue growth, or if the company announces a credible path to positive cash flow. It would downgrade to Sell if quarterly revenue growth decelerates below 50% YoY or if a significant equity offering is announced. Relative to its own history and the extreme cash burn, the stock is overvalued.
Sign up to view all
INSM 12-Month Price Forecast
Insmed is a classic high-risk, high-potential biotech story caught between explosive commercial growth and a financial sustainability crisis. The neutral stance reflects the offsetting forces of compelling 152.6% revenue growth against an unsustainable -$997.58M annual cash burn and a demanding 61x sales valuation. The stock's severe technical breakdown suggests the market is prioritizing the cash burn risk over the growth narrative. The stance would upgrade to bullish on evidence of sequential margin improvement and a credible financing plan that minimizes dilution. It would turn bearish on any material growth deceleration or the announcement of a massively dilutive capital raise.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Insmed, Inc.'s 12-month outlook, with a consensus price target around $136.40 and implied upside of +30.0% versus the current price.
Average Target
$136.40
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$84 - $136
Analyst target range
Analyst coverage for Insmed appears limited based on the provided data, which shows revenue and EPS estimates but no explicit target prices, consensus recommendation, or buy/hold/sell distribution. The data indicates 9 analysts providing estimates, with an average revenue estimate of $6.31 billion and an average EPS estimate of $10.43, implying a forward-looking expectation of a dramatic turnaround to profitability. However, without explicit price targets, it is impossible to calculate implied upside or downside or characterize the consensus sentiment as bullish or neutral.
The implications of limited explicit analyst target data are significant. While institutional ratings from firms like Morgan Stanley, Mizuho, and Wells Fargo show recent actions maintaining 'Overweight' or 'Buy' ratings, the absence of a clear target price range signals high uncertainty. A wide target spread, if it existed, would indicate divergent views on the company's ability to achieve its commercial and pipeline milestones. The recent upgrades, such as Morgan Stanley moving to 'Overweight' from 'Equal Weight' in March 2026, suggest some analysts see value after the price decline, but the lack of quantified targets makes it difficult to gauge the strength of that conviction. This environment of high uncertainty and limited price guidance can contribute to the stock's elevated volatility.
Bulls vs Bears: INSM Investment Factors
The evidence currently tilts bearish, as the company's severe cash burn, widening losses, and extreme valuation present immediate and quantifiable risks that outweigh its impressive revenue growth. The most critical tension in the investment debate is whether the explosive 152.6% revenue growth can accelerate fast enough to outrun the -$997.58 million annual cash burn before the company requires highly dilutive financing. The bear case hinges on execution stumbles or growth deceleration triggering a liquidity crisis, while the bull case requires flawless commercial execution to justify the 61x sales multiple and achieve the analyst-projected $10.43 EPS turnaround.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue of $263.84 million represents a 152.6% year-over-year increase, demonstrating strong commercial uptake for Arikayce and Brinsupri. Sequential quarterly growth from $107.42M to $142.34M to $263.84M indicates accelerating momentum.
- High Gross Margin Profile: The company maintains a robust gross margin of 82.51% in Q4 2025, providing a strong foundation for future profitability once operating expenses are scaled. This high-margin structure is typical of successful biopharmaceuticals.
- Analyst Expects Dramatic Turnaround: The average analyst EPS estimate for the forward period is $10.43, implying a massive swing from deep losses to significant profitability. This expectation, based on input from 9 analysts, underpins a bullish long-term narrative.
- Significant Price Correction: The stock is down 48.54% over six months and trades at $106.91, near the midpoint of its 52-week range ($67.81-$212.75). This severe correction may have priced in near-term risks, creating a potential entry point for growth investors.
Bearish
- Massive and Widening Losses: The Q4 2025 net loss of -$328.49 million is larger than the -$235.55 million loss in Q4 2024, indicating the path to profitability is not imminent. Operating expenses of $467.39M completely consume the high gross profit.
- Unsustainable Cash Burn: Free cash flow was -$294.19 million for Q4 2025 and -$997.58 million on a trailing twelve-month basis. This extreme cash burn necessitates frequent capital raises, posing a severe dilution risk to equity holders.
- Extremely High Valuation Multiple: Despite the price drop, the trailing Price-to-Sales ratio remains at an exceptionally high 61.31x. This valuation demands near-perfect execution of hyper-growth and pipeline success to be justified, leaving little room for error.
- Severe Technical Downtrend: The stock is in a pronounced downtrend, down 20.83% in the past month versus the S&P 500's +6.31% gain, resulting in -27.14% relative underperformance. This signals a fundamental loss of investor confidence, not just market weakness.
INSM Technical Analysis
The prevailing price trend for Insmed is a pronounced and sustained downtrend, with the stock down 48.54% over the last six months and 28.41% over the last three months. As of the current price of $106.91, the stock is trading at approximately 50.2% of its 52-week range (between $67.81 and $212.75), indicating it is positioned near the midpoint but has experienced a severe correction from recent highs, suggesting a breakdown in momentum and potential value-oriented interest after a significant decline. Recent short-term momentum is decisively negative and accelerating the longer-term downtrend, with the stock down 20.83% over the past month, which starkly contrasts with the S&P 500's gain of 6.31% over the same period, resulting in severe relative underperformance of -27.14%. This divergence highlights significant stock-specific negative catalysts or sector rotation, with the sharp decline from above $200 in early December 2025 to current levels signaling a loss of investor confidence rather than a simple market pullback.
Key technical levels are clearly defined, with immediate resistance likely near the recent breakdown level around $135-$140 (the April-May trading range) and major resistance at the 52-week high of $212.75. Support is firmly established at the 52-week low of $67.81. A decisive break below this critical support would signal a continuation of the bearish trend and potentially trigger further technical selling. The stock's beta of 0.894 indicates it has been slightly less volatile than the broader market during this period, but the extreme price drawdown of -52.06% demonstrates that its volatility is driven by idiosyncratic, fundamental risks rather than systematic market moves, which is critical for risk assessment in a biotech context.
Beta
0.89
0.89x market volatility
Max Drawdown
-52.1%
Largest decline past year
52-Week Range
$71-$213
Price range past year
Annual Return
+42.4%
Cumulative gain past year
| Period | INSM Return | S&P 500 |
|---|---|---|
| 1m | -24.8% | +4.6% |
| 3m | -25.1% | +12.6% |
| 6m | -48.6% | +10.4% |
| 1y | +42.4% | +27.0% |
| ytd | -40.8% | +11.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INSM Fundamental Analysis
Insmed's revenue trajectory shows robust growth, with Q4 2025 revenue reaching $263.84 million, representing a year-over-year growth of 152.6%. This growth is driven by the commercial launches of Arikayce and Brinsupri, as evidenced by the sequential increase from $142.34 million in Q3 and $107.42 million in Q2 2025. However, this top-line expansion is occurring alongside massive operating investments, leading to a net loss of -$328.49 million for the quarter. The revenue growth trend is accelerating on a quarterly sequential basis, but the sustainability of this pace as the products mature is a key question for the investment case.
The company is deeply unprofitable, with a net loss of -$328.49 million in Q4 2025 and a trailing net margin of -2.11%. Despite a healthy gross margin of 82.51% for the quarter, these profits are completely consumed by soaring operating expenses, which totaled $467.39 million, primarily from Research and Development ($254.91 million) and SG&A ($212.48 million). The losses are not narrowing; in fact, the net loss widened from -$235.55 million in Q4 2024, indicating the company is prioritizing growth and pipeline investment over near-term profitability, which is typical for commercial-stage biotechs but escalates cash burn concerns.
Balance sheet and cash flow health are significant concerns. The company reported negative free cash flow of -$294.19 million for Q4 2025 and a trailing twelve-month free cash flow of -$997.58 million. While the current ratio of 3.83 indicates sufficient short-term liquidity, the debt-to-equity ratio of 1.04 shows a leveraged capital structure. The negative return on equity of -172.78% and return on assets of -31.11% reflect the immense capital being consumed without generating earnings. The company is heavily dependent on external financing to fund its operations and growth, as internal cash generation is deeply negative, which elevates financial risk and potential dilution risk for equity holders.
Quarterly Revenue
$263843000.0B
2025-12
Revenue YoY Growth
+1.52%
YoY Comparison
Gross Margin
+0.82%
Latest Quarter
Free Cash Flow
$-997575000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INSM Overvalued?
Given the company's negative net income of -$328.49 million for the latest quarter, the primary valuation metric selected is the Price-to-Sales (PS) ratio, as earnings-based multiples are not meaningful. The trailing PS ratio is an exceptionally high 61.31x, while the Enterprise Value-to-Sales ratio is 28.07x, indicating the market is valuing the stock based on its revenue growth potential despite massive losses.
Peer comparison for valuation is challenging due to the lack of provided industry average multiples in the data. However, a PS ratio of 61.31x is extraordinarily high by any standard, even for a high-growth biotech, suggesting the market is pricing in blockbuster revenue potential from its commercial products and pipeline. This premium valuation must be justified by sustained hyper-growth and successful pipeline catalysts to offset the current cash burn and lack of profitability.
Historical context shows the current valuation is near the lower end of its own historical range. The PS ratio has fluctuated wildly, from a high of 214.24x in Q3 2025 to a low of 35.65x in early 2023. The current PS of 61.31x is below the 140.92x reported for Q4 2025, reflecting the significant price correction. Trading below its own recent historical average suggests the market has tempered its growth expectations or is pricing in increased execution risk, but it remains at a level that demands near-perfect commercial execution to be sustained.
PE
-29.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -28x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-32.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on cash sustainability. Insmed reported a Q4 2025 net loss of -$328.49 million and trailing twelve-month free cash flow of -$997.58 million. With a debt-to-equity ratio of 1.04, the company is burning cash at a rate that necessitates external financing. The risk is not just continued losses, but the high probability of significant equity dilution if the company must raise capital at depressed share prices to fund operations, which could permanently impair shareholder value.
Market & Competitive Risks are elevated due to valuation compression and sector sentiment. The stock's trailing PS ratio of 61.31x, though down from recent highs, remains extraordinarily high and vulnerable to de-rating if growth momentum slows even slightly. With a beta of 0.894, the stock has shown less market correlation, but its -52.06% max drawdown demonstrates extreme idiosyncratic risk driven by its binary commercial and pipeline outcomes. The lack of explicit analyst price targets adds to market uncertainty and volatility.
Worst-Case Scenario involves a 'perfect storm' where revenue growth decelerates faster than expected, pipeline catalysts fail, and the company is forced to raise capital amid a loss of investor confidence. This could trigger a downward spiral toward the 52-week low of $67.81. From the current price of $106.91, this scenario implies a potential loss of approximately -37%. Such a decline would likely be accompanied by analyst downgrades and a further compression of the sales multiple, reflecting a failed transition to profitability and sustained dependency on external funding.
FAQ
The key risks are, in order of severity: 1) Financial Sustainability Risk: A -$997.58M TTM cash burn necessitates dilutive financing, with a debt-to-equity of 1.04 adding pressure. 2) Valuation Compression Risk: A 61.31x PS ratio is vulnerable to de-rating if 152.6% revenue growth decelerates. 3) Execution Risk: The company must successfully commercialize two products and advance its pipeline simultaneously. 4) Market Sentiment Risk: The stock has shown -27.14% relative underperformance in one month, indicating fragile investor confidence that can lead to sharp sell-offs on any negative news.
The 12-month forecast is highly bifurcated, with a 50% probability Base Case target range of $110-$150, a 25% probability Bull Case target of $180-$213, and a 25% probability Bear Case target of $68-$100. The Base Case, as the most likely, assumes robust but decelerating revenue growth and a dilutive capital raise that caps near-term upside. The forecast hinges almost entirely on the company's ability to sustain hyper-growth rates to justify its valuation while managing its cash burn. The wide range reflects the binary nature of the underlying commercial and financial outcomes.
INSM is significantly overvalued based on traditional metrics, trading at a trailing Price-to-Sales ratio of 61.31x. This is an extreme multiple even for a high-growth biotech, indicating the market is pricing in near-perfect execution of hyper-growth and pipeline success. While the price has corrected from highs where the PS ratio exceeded 200x, the current level provides no margin of safety given the -$328M quarterly net loss. The valuation implies the market expects a rapid and dramatic transition to the analyst-projected $10.43 EPS, a highly uncertain outcome.
INSM is not a good buy for most investors at current levels due to its extreme risk profile. While the 152.6% revenue growth is impressive, the stock carries a 61.31x sales multiple, a -$997.58 million annual cash burn, and a severe technical downtrend of -48.54% over six months. It could be a speculative buy only for highly risk-tolerant investors who believe the company can achieve its projected $10.43 EPS turnaround without catastrophic dilution, and who are willing to accept potential downside to the $68 support level. For others, it is a 'watch and wait' situation.
INSM is unsuitable for short-term trading due to its high volatility (beta 0.894 but with a -52.06% max drawdown) and lack of near-term catalysts beyond risky binary events. It is theoretically a long-term investment for those betting on its pipeline and commercial portfolio maturing into profitability, but this horizon is measured in years and carries continuous dilution risk. Given the cash burn, the company's very survival as an independent entity over the next 2-3 years is not guaranteed without further financing. Therefore, only investors with a 3-5 year horizon and high risk tolerance should consider it, with the understanding that the path will be extremely volatile.